AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses

/PRNewswire/ -- AbbVie (NYSE: ABBV) will present 46 abstracts across eight types of cancer during the upcoming American Society of Clinical Oncology (ASCO)...

Related Keywords

Geest ,Niedersachsen ,Germany ,United States ,Ludwigshafen ,Rheinland Pfalz ,Argentina ,American ,Lemzoparlimab Lemzo ,Epcoritamab Epco ,Rituximab Ven ,Venclyxto Sm ,Osimertinib Osi ,Telisotuzumab Vedotin Teliso ,Mohamed Zaki ,Telisotuzumab Vedotin ,Navitoclax Monotherapy ,Instagram ,Abbvie Company ,American Society Of Clinical Oncology ,Janssen Biotech Inc ,Genentech ,Linkedin ,Twitter ,European Hematology Association ,Us National Library Of Medicine ,Allergan ,Facebook ,Abbvie Deutschland Gmbh Co ,Translational Research ,National Comprehensive Cancer Network ,A Retrospective Analysis In Community ,Drug Administration ,Exchange Commission ,Youtube ,Development Of Novel Anti ,Eupal International Collaboration ,Roche Group ,Diffuse Large Lymphoma Research Foundation ,Macrophage Properties ,American Society ,Clinical Oncology ,Annual Meeting ,Results From ,Combination With ,Line Treatment ,Older Patients ,Mantle Cell Lymphoma ,Hematologic Malignancies ,Chronic Lymphocytic Leukemia ,Small Lymphocytic Lymphoma ,Follow Up From ,Chronic Lymphocytic ,Treatment Patterns ,With Chronic ,Proton Pump ,During Routine ,Clinical Outcomes ,Patients Receiving Either Ibrutinib ,Retrospective Analysis ,World Clinical Outcomes ,Either Ibrutinib ,Combination With Azacitidine ,Outpatient Setting ,Myelodysplastic Syndromes ,With High Risk Diffuse ,Cell Lymphoma ,Epcoritamab With Rituximab ,With Relapsed ,Diffuse Largeb Cell Lymphoma ,Who Are Eligible ,Cell Transplant ,Stem Cell Transplant ,High Response Rate Even ,Plus Ruxolitinib ,With Myelofibrosis ,Open Label Phase ,With Acute Myeloid Leukemia ,Dose Escalation ,Prior Osi ,With Advanced ,Met Overexpressing ,Cell Lung Cancer ,Lung Cancer ,Advanced Non Small Cell Lung ,Non Small Cell ,Translational Analyses ,First Line Treatment ,Mantle Cell ,Relapsing Chronic Lymphocytic ,After First Line Treatment ,Plus Venetoclax ,Small Lymophocytic ,Year Follow Up From ,Trial Analysis ,Fixed Duration Ibrutinib ,Azacitidine Versus Oral ,Patients With Acute ,First Remission After ,Patients With Acute Myeloid ,Post Remission Granulocyte ,Stimulating Factor Use ,Venetoclax Combination Treatments ,Patients With Newly Diagnosed Acute ,Patients With ,Hypomethylating Agents ,Large Population Based ,Patients With Chronic ,Leukemia With ,Genomic Analyses ,With Targeted ,Resource Utilization ,Lymphocytic Lymphoma ,Children With ,Refractory Acute Myeloid ,Versus Fludarabine ,Chromic Lymphoma ,Without Risk Associated ,Risk Associated Genetic Markers ,Life Efficacy ,Interim Analysis ,Combination With Obinutuzumab ,First Line Chromic Leukemia ,With Venetoclax ,Myeloid Leukemia ,With Anti Neoplastic Agents ,With Non Hodgkin Lymphoma ,Aggressive Non Hodgkin ,Untreated Patients ,Epcoritamab With ,Update From Phase ,Preliminary Phase ,With Gemcitabine ,Diffuse Largeb Cell ,Who Are Ineligible ,Preliminary Safety ,Janssen Biotech ,National Comprehensive Cancer ,Patient Information ,Medication Guide ,Important Venclyxto ,Crcl This ,Allergan Aesthetics ,Private Securities Litigation Reform Act ,Quarterly Reports ,Tyrosine Kinase ,Product Characteristics ,Abbvie Deutschland Gmbh ,Largeb Cell Lymphoma ,Research Foundation ,Clinically Utilized ,Directed Antibodies ,Novel Anti Cd ,Cell Surface ,Cancer Sci Ther ,Abbvie ,